Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently expe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Boudny, Miroslav, Zemanova, Jana, Khirsariya, Prashant, Borsky, Marek, Verner, Jan, Cerna, Jana, Oltova, Alexandra, Seda, Vaclav, Mraz, Marek, Jaros, Josef, Jaskova, Zuzana, Spunarova, Michaela, Brychtova, Yvona, Soucek, Karel, Drapela, Stanislav, Kasparkova, Marie, Mayer, Jiri, Paruch, Kamil, Trbusek, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6959166/
https://ncbi.nlm.nih.gov/pubmed/30975914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.203430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados